Adults who use a GLP-1 have lower macronutrient intake than nonusers, according to data that will be presented at the European Congress on Obesity.
In an analysis of data from adults with overweight or obesity using a health app, researchers found adults using GLP-1s have lower intake of calories, protein, carbohydrates and fat than nonusers. Adults using a GLP-1 were also more likely to skip meals. Valentina Vinelli, PhD, scientific advisor for Robin Health and nutritionist in the department of metabolic health at IRCCS San Raffaele Hospital in Milan, said the findings showed people who use a

Anti-inflammatory treatment with prednisolone on top of standard care in young patients with Kawasaki disease did not reduce risk for coronary lesions, researchers reported.
Current guideline recommendations to initiate anti-inflammatory therapy to reduce coronary aneurysm risk may not apply to high-risk Chinese patients with Kawasaki disease, according to data published in The New England Journal of Medicine.
“Kawasaki disease is an acute vasculitis of unclear cause that mainly affects children younger than 5 years of age. Although reported worldwide, it is most prevalent in Asia, particularly

In this video, Ursula A. Matulonis, MD, discusses a study assessing letrozole alone compared with standard chemotherapy followed by letrozole maintenance in patients with low-grade serous ovarian, fallopian tube or peritoneal carcinoma.
In the phase 3 noninferiority trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, researchers randomly assigned patients who underwent cytoreductive surgery to letrozole (Femara, Novartis) alone or standard treatment with paclitaxel and carboplatin followed by letrozole.
Results showed letrozole alone did not exhibit

The number of U.S. individuals aged under 18 years breathing unhealthy, polluted air where they lived between 2022 and 2024 totaled 33.5 million, or 46% of this population, according to a press release from the American Lung Association.
Considering all ages, the number of Americans breathing unhealthy, polluted air where they lived totaled 152 million (44%). In last year’s State of the Air report, this total was slightly higher at 156 million.
“We have more work to do to clean up the air that everyone breathes, but right now the EPA is making significant rollbacks to critical and lifesaving

Across 2 decades following the marketing of immunoglobulin, no new safety concerns appeared in pediatric adverse event reports associated with its use, according to data published in Pediatric Allergy and Immunology.
“Our analysis of [FDA’s Adverse Event Reporting System] reports did not reveal new safety concerns regarding IG use in pediatric patients,” Shaokui Wei, MD, MPH, epidemiologist in the office of biostatistics and pharmacovigilance at the FDA, and colleagues wrote. “Most reported [adverse events] were labeled events included in the [U.S. package insert] or confounded by the

Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.
Rates improved over time, but several factors — including socioeconomic status, race, ethnicity and insurance coverage — appeared associated with delays in testing.
The findings underscore the need for greater awareness about the importance of next-generation sequencing (NGS), as well as the identification and implementation of strategies that can ensure equitable access to testing, researchers concluded.
“Each patient

The oral Janus kinase inhibitor upadacitinib was well tolerated for moderate to severe inflammatory bowel disease over a median 58 weeks, according to a study published in Clinical Gastroenterology and Hepatology.
Using pooled data from six ulcerative colitis and Crohn’s disease trials, researchers assessed the long-term safety profile of upadacitinib (Rinvoq, AbbVie) at different doses vs. placebo.
They found that serious adverse events including adjudicated major adverse cardiac events (MACE), malignancy and nonmelanoma skin cancer did not occur or, like venous thromboembolism (VTE), were

In this video, Ursula A. Matulonis, MD, discusses results from the RAMP-201 trial of combination avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer with KRAS mutations.
Data presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer showed an overall response rate of 44% with avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem Inc.) and a median duration of response of 31 months.
According to Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute, the response duration is “impressive”